RKDA · Arcadia Biosciences, Inc. · Webcasts, Transcripts & Audio

Substantial doubt about the company's ability to continue as a going concern.

“With cash and cash equivalents of $4.2 million as of June 30, 2026, the Company believes that its existing cash and cash equivalents will not be sufficient to meet its anticipated cash requirements for at least the next 12 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”